The publication reports on a new target: a dopamine receptor. The authors found that the receptor is unique to lung and liver fibroblasts. Stimulating it blocks YAP and TAZ, reducing and reversing the growth and scar-forming abilities of fibroblasts. Stimulating the dopamine receptor in fibroblasts appeared to switch them from a matrix-depositing state that supports fibrosis to a matrix-degrading state that supports resolution or reversal of fibrosis. In lung and liver fibrosis models, the approach reversed the fibrotic process in these organs.

#fibrosis #dopamine #treatment

Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis: ANDREW J. HAAK, ENIS KOSTALLARI, DELPHINE SICARD, GIOVANNI LIGRESTI, KYOUNG MOO CHOI, NUNZIA CAPORARELLO, DAKOTA L. JONES, QI TAN, JEFFREY MERIDEW, ANA M. DIAZ ESPINOSA, AJA ARAVAMUDHAN, JESSICA L. MAIERS, RODNEY D. BRITT, JR., ANJA C. RODEN, CHRISTINA M. PABELICK, Y. S. PRAKASH, SEYED MEHDI NOURAIE, XIAOYUN LI, YINGZE ZHANG, DANIEL J. KASS, DAVID LAGARES, ANDREW M. TAGER, XARALABOS VARELAS, VIJAY H. SHAH, DANIEL J. TSCHUMPERLIN Science Translational Medicine 30 Oct 2019: Vol. 11, Issue 516, eaau6296 DOI: 10.1126/scitranslmed.aau6296

https://stm.sciencemag.org/content/11/516/eaau6296

Rage Video

https://www.youtube.com/watch?v=Y9AQ1hYvnx4&t=4s

Categories: Misc....

Tags: Agonist, decarboxylase, discovery, Dopamine, drd1, fibroblasts, Fibrosis, idiopathic pulmonary fibrosis, Liver, Lung, Pulmonary fibrosis, reversal, reverse, taz, Treatment, yap